Venture Investment Bank for Early Stage Technology Companies We Invest Through:

• Venture Investment Bank for Early Stage Technology Companies

• We Invest Through:– Angel & Institutional Investor Members– Capital Managed Internally

• NASD\Broker Dealer

Who We Are

VCs Don’t Invest in Early Stage Companies

Angels Do!

The Fact is……

SeedSeed ‘A’ Round ‘B+’ Rounds Mezzanine IPO/Exit‘A’ Round ‘B+’ Rounds Mezzanine IPO/Exit

$200k $.5 – $5M $10M+ $10 - $30M $40M+

Capital ChasmCapital Chasm

Early Stage

1. Get out 20 Envelopes

Ten Highly Effective Habits ofSuccessful Angel Investing

2. Be Quick but don’t Hurry

Ten Highly Effective Habits ofSuccessful Angel Investing

3. Invest in Deals you Understand

Ten Highly Effective Habits ofSuccessful Angel Investing

4. Don’t try to change the Company

Ten Highly Effective Habits ofSuccessful Angel Investing

5. Do your own Competitive Analysis Research

Ten Highly Effective Habits ofSuccessful Angel Investing

6. Get to KNOW the Customer

Ten Highly Effective Habits ofSuccessful Angel Investing

7. Really get to KNOW the Team

Ten Highly Effective Habits ofSuccessful Angel Investing

8. Never, ever Fall in Love

Ten Highly Effective Habits ofSuccessful Angel Investing

9. Know the Intellectual Property

Ten Highly Effective Habits ofSuccessful Angel Investing

10. Know who you pass the Baton to – before you invest

Ten Highly Effective Habits ofSuccessful Angel Investing

Our Value Propositionis

Superior Deal Selection&

Superior Deal Support

• Initial Screening by Angel Capital Staff• Qualified Deals go to Expert Angel

Members for Analysis• Engage VCs in Due Diligence Review• Engage Relevant Strategic Investors

Deal Selection Process

• Angel Investors with Deep Relevant Industry Experience Willing to:– Invest– Serve as Advisors

• VCs Willing to Fund Later Rounds Based on Certain Milestones

• Defensible IP

Deal Selection Criteria

• Introduce:– Expert Angels Who Invest and Join Board– Industry Board Members– Strategic Relationships– VCs with Relevant Expertise

• Valuation and Deal Structure• Ongoing Corporate Finance Services

Deal Support

• Disruptive Technology in Intelligent Storage Networks

• 12 patents filed, more to come• Market projected to grow 900% by 2003 to $6.7B• Experienced management team has built two

successful companies• Elite industry board• Key industry relationships in place

BioRight International, Inc.

Breakthrough Nonprescription Cold& Allergy Medicines

•Launched 11/00 - Sales Exceeding $1.3 Million•Distribution in Over 22,000 Retail Pharmacies – Walgreens, Rite-Aid, Eckerds, Safeway, Osco, Longs•Pipeline for New Product Introductions•Revenue Growth to Over $100 Million Within 5 Years•Management Combines Medical Expertise With 25 Year Track Record of Retail Product Introductions

• Multifocal Contact Lens With Strong Patents and High Consumer Demand

• Clinical Data Consistently Outperforms Any Lens on the Market (Including J&J Acuvue)

• FDA Approval Received for:– Custom (Lathed Lens) Launched in US and Canada– Cast Molded Lens (Disposable & Mass Produced)

• CE Mark Received for Astigmatic Intraocular Lens

• Mike Pogue - President– (415) 289-4618– [email protected]

Contact Information